Royal Prima PT (PRIM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Royal Prima PT (PRIM) has a cash flow conversion efficiency ratio of 0.002x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rp1.86 Billion ≈ $108.71K USD) by net assets (Rp955.60 Billion ≈ $55.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Royal Prima PT market cap and net worth for the company's overall valuation and market capitalisation.
Royal Prima PT - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Royal Prima PT's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Royal Prima PT Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Royal Prima PT ranked by their cash flow conversion efficiency. Explore Royal Prima PT cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kyobo 3 SPAC
KQ:208710
|
0.033x |
|
Smartlink Holdings Limited
NSE:SMARTLINK
|
0.022x |
|
Inventec Besta Co Ltd
TW:8201
|
-0.006x |
|
Lithium Energy Ltd
AU:LEL
|
-0.041x |
|
Zee Learn Limited
NSE:ZEELEARN
|
0.024x |
|
Rifa Ind
KO:000760
|
0.011x |
|
HAMILTON GLB.OPP.LS-0001
F:5DS
|
N/A |
|
Shiva Texyarn Limited
NSE:SHIVATEX
|
0.092x |
Annual Cash Flow Conversion Efficiency for Royal Prima PT (2014–2024)
The table below shows the annual cash flow conversion efficiency of Royal Prima PT from 2014 to 2024. View latest Royal Prima PT stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Rp962.38 Billion ≈ $56.39 Million |
Rp46.98 Billion ≈ $2.75 Million |
0.049x | +125.21% |
| 2023-12-31 | Rp981.10 Billion ≈ $57.49 Million |
Rp21.27 Billion ≈ $1.25 Million |
0.022x | -1.33% |
| 2022-12-31 | Rp982.66 Billion ≈ $57.58 Million |
Rp21.59 Billion ≈ $1.27 Million |
0.022x | -90.97% |
| 2021-12-31 | Rp964.21 Billion ≈ $56.50 Million |
Rp234.54 Billion ≈ $13.74 Million |
0.243x | +259.56% |
| 2020-12-31 | Rp889.35 Billion ≈ $52.11 Million |
Rp60.16 Billion ≈ $3.53 Million |
0.068x | +1830.15% |
| 2019-12-31 | Rp851.17 Billion ≈ $49.88 Million |
Rp2.98 Billion ≈ $174.81K |
0.004x | -91.58% |
| 2018-12-31 | Rp848.87 Billion ≈ $49.74 Million |
Rp35.33 Billion ≈ $2.07 Million |
0.042x | -53.08% |
| 2017-12-31 | Rp250.42 Billion ≈ $14.67 Million |
Rp22.22 Billion ≈ $1.30 Million |
0.089x | -96.16% |
| 2016-12-31 | Rp12.13 Billion ≈ $710.64K |
Rp28.02 Billion ≈ $1.64 Million |
2.310x | +135.31% |
| 2015-12-31 | Rp722.89 Million ≈ $42.36K |
Rp-4.73 Billion ≈ $-277.14K |
-6.543x | -274.24% |
| 2014-12-31 | Rp-2.10 Billion ≈ $-123.29K |
Rp3.68 Billion ≈ $215.54K |
-1.748x | -- |
About Royal Prima PT
PT Royal Prima Tbk engages in providing hospital services in Indonesia. The company operates its hospitals under the Royal Prima Medan, Royal Prima Jambi, and RSU Royal Prima Marelan names. It provides health services, such as emergency, outpatient, inpatient, laboratorium, radiology, medical rehab, pharmacy, and MCU; and general surgery, internist, VCT, ICU, cardiology, urology, haemodialysis, m… Read more